Literature DB >> 11172957

Radiation therapy in the treatment of endometrial stromal sarcoma.

H D Weitmann1, T H Knocke, H Kucera, R Pötter.   

Abstract

OBJECTIVE: The efficacy of radiation therapy in the treatment of endometrial stromal sarcoma (ESS) is still not clear. We report our results over an 18-year period in comparison to data from literature concerning adjuvant radiation therapy and other treatment modalities. PATIENTS AND METHODS: During 1981-1998, 21 patients with ESS were treated at General Hospital Vienna. The age of the patients ranged between 44-76 years (median: 65 yr). The 1989 FIGO classification for endometrial carcinoma was used in this study retrospectively. Eleven patients presented in Stage I, 1 in Stage II and 5 in Stage III. Four patients had Stage IV tumors or recurrences. The majority of patients (66.7%) had a Grade 3 tumor. Seventeen patients were treated in a curative intent. Fifteen patients were referred for postoperative radiotherapy after hysterectomy. Thirteen of them received a combined radiotherapy. Two patients were referred for primary radiotherapy. They received a combined radiotherapy. Four patients were referred for radiotherapy with a palliative intent. Twenty patients received external beam therapy (EBT) in daily fractions of 1.6-2.0 Gy up to a total dose of 27-57 Gy to the pelvis. Seventeen patients received brachytherapy.
RESULTS: Follow-up was 8 to 170 months (mean: 70.3 months, median: 64 months). Eleven patients are still alive, 10 without tumor and 1 with tumor. Ten patients are dead, 6 due to ESS, 1 due to breast cancer, and 3 due to intercurrent diseases. After adjuvant radiotherapy, 3 patients had tumor recurrences. All had distant metastases, and 1 had local failure additionally. Two patients with primary treatment died due to intercurrent disease without tumor. The overall actuarial survival and the disease-specific survival rates were 63.4% and 80.9% after 5 years and 52.8% and 80.9% after 10 years. The overall local control rate was 93.8% after 5 years. Four patients treated with a palliative intent showed partial response. Three patients died rapidly due to tumor. One patient with a Grade 1 tumor is still alive 12 months after treatment.
CONCLUSION: In our experience, surgery and adjuvant radiation therapy are most effective treatments for patients with ESS due to the excellent local control in all stages and the good disease-specific survival in early stages.

Entities:  

Mesh:

Year:  2001        PMID: 11172957     DOI: 10.1016/s0360-3016(00)01369-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

1.  Long-term medroxyprogesterone acetate therapy for low-grade endometrial stromal sarcoma.

Authors:  Mika Mizuno; Yasushi Yatabe; Akihiro Nawa; Toru Nakanishi
Journal:  Int J Clin Oncol       Date:  2011-08-10       Impact factor: 3.402

Review 2.  High-grade undifferentiated sarcomas of the uterus: diagnosis, outcomes, and new treatment approaches.

Authors:  Charles-André Philip; Patricia Pautier; Florence Duffaud; Isabelle Ray-Coquard
Journal:  Curr Oncol Rep       Date:  2014-10       Impact factor: 5.075

3.  Treatment of pure uterine sarcoma at the Institut Català D'Oncologia.

Authors:  Gonçalo Fernandez; Susanna Marín I Borràs; Valentín Navarro Pérez; Ferran Guedea
Journal:  Rep Pract Oncol Radiother       Date:  2013-01-16

4.  Endometrial stromal sarcoma of the uterus presenting as pulmonary metastasis.

Authors:  Fariba Binesh; Shokouh Taghipour Zahir; Ali Akhavan; Taghi Roshan Bovanlu
Journal:  BMJ Case Rep       Date:  2013-08-01

Review 5.  Uterine sarcoma 2008.

Authors:  Jeff F Lin; Brian M Slomovitz
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

6.  Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).

Authors:  D Denschlag; F C Thiel; S Ackermann; P Harter; I Juhasz-Boess; P Mallmann; H-G Strauss; U Ulrich; L-C Horn; D Schmidt; D Vordermark; T Vogl; P Reichardt; P Gaß; M Gebhardt; M W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-10       Impact factor: 2.915

7.  Endometrial stromal sarcomas: a retrospective analysis of 28 patients, single center experience for 20 years.

Authors:  Eun Ji Nam; Jae Wook Kim; Dae Woo Lee; Si Young Jang; Jong Wook Hong; Young Tae Kim; Jae Hoon Kim; Sunghoon Kim; Sang Wun Kim
Journal:  Cancer Res Treat       Date:  2008-03-31       Impact factor: 4.679

8.  Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019).

Authors:  Dominik Denschlag; Sven Ackermann; Marco Johannes Battista; Wolfgang Cremer; Gerlinde Egerer; Markus Follmann; Heidemarie Haas; Philipp Harter; Simone Hettmer; Lars-Christian Horn; Ingolf Juhasz-Boess; Karin Kast; Günter Köhler; Thomas Kröncke; Katja Lindel; Peter Mallmann; Regine Meyer-Steinacker; Alexander Mustea; Edgar Petru; Peter Reichardt; Dietmar Schmidt; Hans-Georg Strauss; Clemens Tempfer; Falk Thiel; Uwe Ulrich; Thomas Vogl; Dirk Vordermark; Paul Gass; Matthias W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-10-22       Impact factor: 2.915

Review 9.  Treatment of early uterine sarcomas: disentangling adjuvant modalities.

Authors:  Flora Zagouri; Athanasios-Meletios Dimopoulos; Stelios Fotiou; Vassilios Kouloulias; Christos A Papadimitriou
Journal:  World J Surg Oncol       Date:  2009-04-08       Impact factor: 2.754

10.  Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.

Authors:  Carmen Balañá; Enrique de Álava; Ruth Sardinha; Teresa Hernández; Susana Fraile; Francesc Tresserra; August Vidal; Maria Carmén Gómez; Aurora Astudillo; Nieves Hernández; Javier Saenz de Santamaría; Jaume Ordi; Luis Gonçalves; Rafael Ramos
Journal:  Clin Sarcoma Res       Date:  2013-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.